<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001959</url>
  </required_header>
  <id_info>
    <org_study_id>000042</org_study_id>
    <secondary_id>00-DK-0042</secondary_id>
    <nct_id>NCT00001959</nct_id>
  </id_info>
  <brief_title>Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)</brief_title>
  <official_title>Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effectiveness of the drug pirfenidone in treating focal segmental
      glomerulosclerosis (FSGS). Patients with this disease have kidney fibrosis (scarring) and
      proteinuria (excessive excretion of protein in the urine). About half of patients with FSGS
      eventually require kidney dialysis or transplant. Steroids, which are currently used to treat
      the disease, are effective in only a minority of patients. Other drugs, such as cyclosporin
      and cyclophosphamide, improve proteinuria in a very small percentage of patients and have
      serious side effects.

      Patients with FSGS who wish to participate in this study will undergo pre-study evaluation
      with blood and urine tests. Patients must be on a stable dose of an ACE inhibitor (a drug
      that lowers blood pressure and reduces proteinuria) for at list 6 months before starting
      pirfenidone therapy. (Patients who are not already taking an ACE inhibitor will be started on
      the drug; those who cannot tolerate ACE inhibitors will be given a different drug.) Patients
      with elevated cholesterol will take a cholesterol-lowering drug. A diet containing
      approximately 1 gram of protein per kilogram of body weight per day will be recommended.

      Patients will take pirfenidone by mouth 3 times a day for 12 months. Blood and urine will be
      tested once a month, either at NIH or by the patient's local kidney specialist. They will
      collect two 24-hour urine samples at the beginning of the treatment period, at 2-month
      intervals throughout the study, and at a 6-month follow-up. Patients will also be asked to
      give three to five tubes of blood and urine samples for analysis during the study.

      In animal studies, pirfenidone improved kidney function and proteinuria and reduced kidney
      scarring in rats with a disease similar to FSGS. In human studies, pirfenidone improved
      breathing and survival in patients with lung fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this pilot phase II trial is to evaluate the ability of pirfenidone, a novel
      anti-fibrotic agent, to reduce the proteinuria and slow the rate of progression of renal
      insufficiency in patients with focal segmental glomerulosclerosis (FSGS). We will enroll 25
      patients with renal biopsy proven FSGS and evidence of impaired renal function (glomerular
      filtration rate, GFR, of 10-80 ml/min; after 1/02 must have GFR greater than 25 ml/min) as
      assessed by the 4 variable Modification of Diet in Renal Disease equation. As standard of
      care therapy, all patients will also receive angiotensin converting enzyme inhibitor (ACEI)
      therapy, and will receive an HMG Co-A reductase inhibitor drug if hypercholesterolemic.
      Preliminary evaluation will assure that the patients meet the study requirements, and an
      evaluation period will be used to ensure that patients are on maximal conservative therapy
      prior to the baseline period. Patients will receive treatment with pirfenidone daily, with
      dose adjusted for body weight and level of kidney function. The primary end point will be the
      decrease glomerular filtration as a marker of glomerular injury; reduction in proteinuria
      will be a secondary end-point. If the pilot study suggests this drug delays progression of
      renal insufficiency or reduces proteinuria in patients with FSGS, we will proceed with a
      large scale randomized, placebo-controlled study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in GFR During Treatment Period</measure>
    <time_frame>12 months from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proteinuria After Treatment</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Positive Change in GFR</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Fibrosis</condition>
  <condition>Focal Glomerulosclerosis</condition>
  <condition>Kidney Failure</condition>
  <condition>Nephrotic Syndrome</condition>
  <condition>Proteinuria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Adults greater than or equal to 18 years of age.

               2. Patients will provide informed consent.

               3. Biopsy proven FSGS.

               4. Glomerular filtration rate of at least 25 and no more than 80 ml/minute as
                  assessed by the 4 variable Modification of diet in renal disease GFR equation.

               5. At least 6 months of renal function data must be available prior to the patient's
                  receiving pirfenidone, and renal function must show a rate of decline of greater
                  than or equal to 0.4 ml/min/month during this baseline period.

               6. Patients must have received no glucocorticoids, cyclophosphamide, mycophenolate
                  or other immunosuppressive drugs for at least 2 months prior to the study period.

               7. Patients must have received no cyclosporin for at least 6 months prior to the
                  study period.

               8. Patients must have been taking an angiotensin converting enzyme inhibitor (ACEI)
                  or angiotensin receptor blocker (ARB) at a stable dose for at least 6 months,
                  unless intolerant of both classes of medication.

               9. Patients who are HIV seropositive will receive standard care for HIV disease
                  (patients receiving immune-modulating therapy will be excluded).

              10. Women with child-bearing potential must maintain an effective birth control
                  regimen (oral contraceptive, intrauterine device, barrier plus spermicide).

              11. Men will be advised that although Ames testing has been negative for any evidence
                  of mutagenicity, they should consider use of contraceptives during the study
                  period as well.

        EXCLUSION CRITERIA:

          1. Inability to give informed consent or cooperate with study.

          2. Known intolerance to pirfenidone.

          3. Evidence of FSGS associated with an additional primary or secondary glomerular disease
             (e.g. diabetes, membranous nephropathy, IgA nephropathy).

          4. Recent (within 6 months) history of myocardial infarction.

          5. History of peptic ulcer within 6 months.

          6. History of cerebrovascular disease manifested by transient ischemic attack or
             cerebrovascular accident within 6 months.

          7. Pregnancy, breast feeding or inadequate birth control.

          8. History of photosensitivity dermatitis.

          9. Concurrent drug treatment with gemfibrozil, cyclosporin or erythromycin,
             potassium-sparing diuretics and other drugs which may potentiate hyperkalemia, or
             concurrent immunosuppresive medications.

         10. Requirement for NSAID therapy.

         11. Requirement for interleukin-2 therapy or other immune-modulating medication.

         12. Existence of any other condition which would complicate the implementation or
             interpretation of the study.

         13. Renal transplant.

         14. Evidence of significant hepatic disease, as indicated by serum transaminases greater
             than 3 times upper limit of normal, protime greater than 2 seconds prolonged.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/B_2000-DK-0042.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Abbate M, Zoja C, Rottoli D, Corna D, Perico N, Bertani T, Remuzzi G. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol. 1999 Apr;10(4):804-13.</citation>
    <PMID>10203365</PMID>
  </reference>
  <reference>
    <citation>BÃ³di I, Kimmel PL, Abraham AA, Svetkey LP, Klotman PE, Kopp JB. Renal TGF-beta in HIV-associated kidney diseases. Kidney Int. 1997 May;51(5):1568-77.</citation>
    <PMID>9150474</PMID>
  </reference>
  <reference>
    <citation>Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994 Nov 10;331(19):1286-92. Review.</citation>
    <PMID>7935686</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2000</study_first_submitted>
  <study_first_submitted_qc>January 18, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2000</study_first_posted>
  <results_first_submitted>June 16, 2010</results_first_submitted>
  <results_first_submitted_qc>April 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2012</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Jeffrey Kopp, M.D.</investigator_full_name>
    <investigator_title>Staff Clinician</investigator_title>
  </responsible_party>
  <keyword>Fibrosis</keyword>
  <keyword>Nephrotic Syndrome</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Renal Failure</keyword>
  <keyword>TGF-Beta</keyword>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <keyword>FSGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>21 adults patients were enrolled between 2000-2004 at the clinical center of NIH</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pirfenidone</title>
          <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>newly diagnosed colon cancer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>disabling sedation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pirfenidone</title>
          <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline GFR</title>
          <units>ml/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline period proteinuria</title>
          <units>g/d</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" lower_limit="1.6" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Decrease in GFR during baseline period</title>
          <units>ml/min/1.73 m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.61" lower_limit="-1.31" upper_limit="-0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of angiotensin antagonist therapy before treatment</title>
          <description>2 patients did not receive angiotensin antagonist therapy during the baseline periods because of angioedema and hypotension.</description>
          <units>month</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="8.4" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decrease in GFR During Treatment Period</title>
        <time_frame>12 months from baseline</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in GFR During Treatment Period</title>
          <population>ITT</population>
          <units>ml/min/1.73 m2</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" lower_limit="-0.78" upper_limit="-0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>H0: GFR Decrease during baseline period and treatment period are same</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proteinuria After Treatment</title>
        <time_frame>12 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
          </group>
        </group_list>
        <measure>
          <title>Proteinuria After Treatment</title>
          <units>g/d</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="1.2" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>H0: Proteinuria during baseline and treatment periods are same</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Positive Change in GFR</title>
        <time_frame>12 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pirfenidone</title>
            <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Positive Change in GFR</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 months</time_frame>
      <desc>Include all adverse events either judged to be related to the study or unrelated to the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Pirfenidone</title>
          <description>During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colon cancer (unrelated to the trial)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated liver enzymes (judged possibly related to the trial)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Death (unrelated to the trial)</sub_title>
                <description>traumatic subdural hematoma</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal discomfort</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation or fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>photosensitivity dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No control group, measurement imprecision, results may not applicable to all patients with FSGS, needs histologic evidence to support our findings, Optimal dosage needs to be identified.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey B Kopp, MD</name_or_title>
      <organization>NIDDK, NIH</organization>
      <phone>3015943403</phone>
      <email>jbkopp@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

